Category Archives: Benign-by-Design

Integrating Sustainability into Pharma Manufacturing

Posted on June 1, 2023 by Saharsh Davuluri

Respected Irish business Niall FitzGerald once said, “Sustainability is here to stay or we may not be.” A supporter of sustainable business initiatives in Europe, he has also pointed out…

Posted in Benign-by-Design, Chemistry, corporate stewardship, ESG | Comments Off

Synthetic Route Scouting: Factors to Improve API Manufacturing

Posted on January 7, 2018 by Saharsh Davuluri

Synthetic route selection is a crucial element in API manufacturing. While the requirements of the synthetic process of a drug will naturally evolve during its life cycle, scouting alternate routes…

Posted in API synthesis, APIs, atom economy, Benign-by-Design, Chemistry, Contract Manufacturing, CRO/CMO, green chemistry, method development, Neuland Labs, outsourcing, process chemistry, Process Engineering, Route Design, Route Scouting, scale-up, Synthesis Route | Comments Off

Embracing Green Chemistry

Posted on December 20, 2015 by Saharsh Davuluri

There’s an article on Piramal’s Pharma Solutions division at PharmTech about how they are encouraging pharma companies to implement green chemistry earlier in the drug development cycle. Yes, we agree…

Posted in analytical science, API synthesis, APIs, atom economy, Benign-by-Design, Chemistry, CMC, Contract Manufacturing, corporate stewardship, EHS, energy conservation, energy effciency, green chemistry, method development, Neuland Labs, Route Design, Route Scouting, synthesis, Synthesis Route | Comments Off

Green Chemistry and Benign by Design

Posted on September 6, 2015 by Saharsh Davuluri

7 ways to boost profits and reduce pharma synthesis waste At Neuland, we’re advocates of green chemistry. Not only is it better for the environment, but it’s also just logistically…